Canadian Non-Interventional Prospective Cohort Study on the Real - Life Assessment of Abilify Maintena in Schizophrenia

Trial Profile

Canadian Non-Interventional Prospective Cohort Study on the Real - Life Assessment of Abilify Maintena in Schizophrenia

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms ReLiAM
  • Sponsors Lundbeck Canada
  • Most Recent Events

    • 24 May 2017 Results of an interim analysis at 12-months (n=192), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 09 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Feb 2017.
    • 21 Nov 2016 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top